Results 21 to 30 of about 23,148 (170)
PPAR Research, 2018 Nonalcoholic fatty liver disease or steatohepatitis (NAFLD/NASH) is a fatty liver disease that is closely related to obesity, diabetes, and dyslipidemia. Pioglitazone, which was developed as an antidiabetic drug, is known to improve NALFD.
Hwa Young Ahn +5 more
doaj +1 more source
Scientific Reports, 2023 Pioglitazone is an insulin resistance inhibitor widely used as monotherapy or combined with metformin or insulin in treating type 2 diabetes mellitus (T2DM).
Hsin-Chung Lin +8 more
doaj +1 more source
Journal of Lipid Research, 2010 Pioglitazone, a hypoglycemic agent, has been shown to increase plasma HDL cholesterol, but the mechanism is incompletely understood. We further investigated effects of pioglitazone on transcriptional regulation of apolipoprotein (apo)A-I gene and ...
Lin-Hua Zhang +4 more
doaj +1 more source
Effects of Pioglitazone on Stearoyl-CoA Desaturase in Obese Zucker fa/fa Rats
Journal of Pharmacological Sciences, 2007 The effects of a peroxisome proliferator activated receptor γ (PPARγ) agonist on hepatic stearoyl-CoA desaturase (SCD) in insulin-resistant and obese Zucker fa/fa rats were studied.
Tomoaki Toyama +5 more
doaj +1 more source
Direct inhibitory effects of pioglitazone on hepatic fetuin-A expression. [PDF]
PLoS ONE, 2014 Fetuin-A, a circulating glycoprotein synthesized in the liver, is involved in insulin resistance and type 2 diabetes. However, regulation of fetuin-A synthesis has remained obscure. We previously reported that pioglitazone treatment significantly reduced
Akinobu Ochi +10 more
doaj +1 more source
The Effect of Co-administration of Pioglitazone and Simvastatin on Insulin Resistance Parameters and PPAR.γ Expression in Insulin-resistant Rats [PDF]
Journal of Kerman University of Medical Sciences, 2017 Backgrounds: Insulin resistance is a pathological condition associated with metabolic syndrome. In this condition, insulin action in liver, muscles, and adipocytes decreases which leads to hyperglycemia, hyperinsulinemia, and dyslipidemia ...
Gholam Abbas Mohammadi +3 more
doaj
Cardiovascular Diabetology, 2017 Background and aims Pioglitazone targets multiple pathogenic pathways involved in the development of cardiovascular diseases (CVD). The aim of this systematic review and meta-analysis is to assess the effects of pioglitazone treatment on the secondary ...
Marit de Jong +4 more
doaj +1 more source
Comparison of Vildagliptin and Pioglitazone in Korean Patients with Type 2 Diabetes Inadequately Controlled with Metformin [PDF]
Diabetes & Metabolism Journal, 2016 BackgroundWe compared the efficacies of vildagliptin (50 mg twice daily) relative to pioglitazone (15 mg once daily) as an add-on treatment to metformin for reducing glycosylated hemoglobin (HbA1c) levels in Korean patients with type 2 diabetes ...
Jong Ho Kim +16 more
doaj +1 more source
Current clinical evidence on pioglitazone pharmacogenomics
Frontiers in Pharmacology, 2013 Pioglitazone is the most widely used thiazolidinedione and acts as an insulin-sensitizer through activation of the Peroxisome Proliferator-Activated Receptor-γ (PPARγ).
Marina eKawaguchi-Suzuki +1 more
doaj +1 more source